RANDOMIZED TRIAL OF COMBINED MODALITY THERAPY (5000 R + 5FU + MECCNU) VS COMBINATION CHEMOTHERAPY (5FU + MECCNU) IN TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER

被引：0
|
作者：
LIVSTONE, EM [1 ]
机构：
[1] YALE UNIV,NEW HAVEN,CT 06520
来源：
GASTROENTEROLOGY | 1978年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1057 / 1057
页数：1
相关论文
共 50 条
  • [21] Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/Oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000-05 trial
    Boige, V.
    Castaing, M.
    Loriot, M. A.
    Barrois, M.
    Miran, I.
    Mulot, C.
    Pignon, J. R.
    Ducreux, M.
    Laurent-Puig, R.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 240 - 241
  • [22] Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000-05 trial
    Castaing, M., Jr.
    Loriot, M. A.
    Barrois, M.
    Miran, I.
    Mulot, C.
    Laurent-Puig, P.
    Pignon, J. P.
    Ducreux, M.
    Boige, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Hydroxyurea, folinic acid, 5FU bolus and infusion (HLFP regimen) in advanced gastric cancer
    Louvet, C
    deGramont, A
    Beerblock, K
    Mal, F
    Ciribilli, JM
    Varette, C
    Demuyck, B
    Raymond, E
    Gamelin, E
    Colin, P
    Krulik, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : 557 - 557
  • [24] Randomized phase 3 trial of irinotecan (CPT-11)+5FU/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients
    Dank, M
    Zaluski, J
    Barone, C
    Valvere, V
    Peschel, C
    Wenczl, M
    Goker, E
    Risse, ML
    Awad, L
    Bugat, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 308S - 308S
  • [25] The role of levamisole (LEV) in the adjuvant treatment of stage III colon cancer (CC): A randomized trial of LEV and 5-fluorouracil (5FU) versus 5FU alone on behalf of "Colon Adiuvante Marche".
    Catalano, V
    Cascinu, S
    Silva, RR
    Mattioli, R
    Marcellini, M
    Pancotti, A
    Bascioni, R
    Torresi, U
    Catalano, G
    Cellerino, R
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 52 - 52
  • [26] Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer
    Aballea, S.
    Najib, M.
    Cure, S.
    O'Neil, B.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 66 - 66
  • [27] 'Tomudex' (raltitrexed) plus 5FU combination treatment for patients with advanced colorectal cancer: a Phase I study
    Mayer, S
    Hilger, R
    Muller, C
    Dohmen, D
    Kloeppel, R
    Vanhoefer, U
    Scheulen, ME
    Seeber, S
    Harstick, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S74 - S74
  • [28] Schedule dependency of 5-fluorouracil (5FU) chemotherapy in patients with advanced colorectal cancer: A systematic review\ .
    Barrajon, E
    Esquerdo, G
    Lopez, A
    Llorca, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 161S - 161S
  • [29] CHEMOTHERAPY OF ADVANCED COLORECTAL-CANCER AND OTHER MALIGNANCIES WITH 5-FLUOROURACIL (5FU) AND ANGUIDINE (ANG)
    MURPHY, WK
    VALDIVIESO, M
    BURGESS, MA
    BODEY, GP
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 419 - 419
  • [30] Randomized phase 2 trial of radiation with either gemcitabine or 5FU/cisplatin in bladder cancer
    Shipley, W. U.
    Zhang, P.
    Saylor, P.
    Lee, C.
    Wu, C. L.
    Parker, W.
    Lautenschlaeger, T.
    Zietman, A.
    Efstathiou, J.
    Jani, A.
    Kucuk, O.
    Souhami, L.
    Rodgers, J.
    Sandler, H.
    Coen, J.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S24 - S25
12345